No profile data available.
Adlai Nortye Ltd. (ANL) is a healthcare company in the additional cancer treatment drugs industry, based in Grand Cayman, Cayman Islands, with about 123 full-time employees.
It reported revenue of $5.00 million for fiscal year 2025, and net income of -$35.53 million. Its market capitalization was $44.28 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Adlai Nortye reported $5.00 million in revenue for fiscal year 2025.
$44.28 million as of December 4, 2025.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Elicio Therapeutics, Inc. (ELTX), Werewolf Therapeutics, Inc. (HOWL), Instil Bio, Inc. (TIL), NextCure, Inc. (NXTC).